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PValvular Heart Disease
Percutaneous Mitral Repair With the MitraClip System
Safety and Midterm Durability in the Initial EVEREST
(Endovascular Valve Edge-to-Edge REpair Study) Cohort
Ted Feldman, MD,* Saibal Kar, MD,† Michael Rinaldi, MD,‡ Peter Fail, MD,§
James Hermiller, MD, Richard Smalling, MD, PHD,¶ Patrick L. Whitlow, MD,#
William Gray, MD,** Reginald Low, MD,†† Howard C. Herrmann, MD,‡‡ Scott Lim, MD,§§
Elyse Foster, MD, Donald Glower, MD,¶¶ for the EVEREST Investigators
Evanston, Illinois; Los Angeles, Sacramento, and San Francisco, California; Charlotte and Durham,
North Carolina; Houma, Louisiana; Indianapolis, Indiana; Houston, Texas; Cleveland, Ohio;
New York, New York; Philadelphia, Pennsylvania; and Charlottesville, Virginia
Objectives We undertook a prospective multicenter single-arm study to evaluate the feasibility, safety, and efficacy of the
MitraClip system (Evalve Inc., Menlo Park, California).
Background Mitral valve repair for mitral regurgitation (MR) has been performed by the use of a surgically created double
orifice. Percutaneous repair based on this surgical approach has been developed by use of the Evalve MitraClip
device to secure the mitral leaflets.
Methods Patients with 3 to 4 MR were selected in accordance with the American Heart Association/American College of
Cardiology guidelines for intervention and a core echocardiographic laboratory.
Results A total of 107 patients were treated. Ten (9%) had a major adverse event, including 1 nonprocedural death. Freedom
from clip embolization was 100%. Partial clip detachment occurred in 10 (9%) patients. Overall, 79 of 107 (74%)
patients achieved acute procedural success, and 51 (64%) were discharged with MR of 1. Thirty-two patients
(30%) had mitral valve surgery during the 3.2 years after clip procedures. When repair was planned, 84% (21 of 25)
were successful. Thus, surgical options were preserved. A total of 50 of 76 (66%) successfully treated patients were
free from death, mitral valve surgery, or MR 2 at 12 months (primary efficacy end point). Kaplan-Meier freedom
from death was 95.9%, 94.0%, and 90.1%, and Kaplan-Meier freedom from surgery was 88.5%, 83.2%, and 76.3%
at 1, 2, and 3 years, respectively. The 23 patients with functional MR had similar acute results and durability.
Conclusions Percutaneous repair with the MitraClip system can be accomplished with low rates of morbidity and mortality and
with acute MR reduction to  2 in the majority of patients, and with sustained freedom from death, surgery, or re-
current MR in a substantial proportion (EVEREST I; NCT00209339. EVEREST II; NCT00209274). (J Am Coll Cardiol
2009;54:686–94) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.077l
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Mitral valve (MV) repair with the use of a surgical approach
o create a double-orifice valve was first performed by Alfieri
n 1991 (Fig. 1) (1–3). Durable results in surgically-treated
atients without annuloplasty have been described in se-
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August 18, 2009:686–94 Percutaneous Mitral Repair With the MitraClip Systemevice (Evalve, Inc., Menlo Park, California) is delivered to
he MV via percutaneous femoral venous transseptal access.
he clip is aligned above the MV and advanced across the
itral orifice before grasping and coapting the leaflets.
ix-month results of percutaneous mitral repair for mitral
egurgitation (MR) by use of the MitraClip system was
reviously reported in a cohort of 55 patients (8). This
eport details clinical results in a cohort of the first 107
atients followed for as long as 3 years. This therapy uses a
rst-in-class catheter-based percutaneous device for the
reatment of degenerative and functional MR, and results,
ncluding all patients at 12 months and a number of patients
ith more than 1-year follow-up, are reported.
ethods
tudy design. This is a prospective, multicenter, single-
rm study. The objective was to evaluate the feasibility,
afety, and efficacy of the MitraClip device. The study was
pproved by the Food and Drug Administration, Health
anada, and all of the participating local institutional review
oards and Canadian ethics boards. All patients gave
nformed written consent. All echocardiograms were re-
iewed by a core laboratory.
Study sites were selected for expertise in both catheter
pproaches to valvular heart disease and with surgical repair.
nterventional operators all had experience with transseptal
uncture. Ninety percent of sites (28 of 31) have a surgeon
nvestigator who performed 25 MV surgeries yearly.
hirty-one North American sites enrolled 107 patients, and
0% of procedures represent first, second, or third proce-
ures at a site (Online Appendix).
Figure 1 Double Orifice Surgical MV Repair With Suture
Illustration depicts a double-orifice mitral valve (MV) surgical repair. The MV is
viewed from the left atrial side. The middle scallops of the anterior and poste-
rior leaflets have been sutured together, which creates a double orifice, edge-
to-edge, or bow-tie repair.ptudy population. The study in-
ludes 55 patients treated in the
VEREST (Endovascular Valve
dge-to-Edge REpair Study)
hase I feasibility trial, and 52
oll-in patients treated in the
VEREST II pivotal trial, who
epresent the pre-randomization
tart-up experience.
itraClip system. The Mitra-
lip system uses a tri-axial cath-
ter system with an implantable
lip. The Guide Catheter is 24-F
roximally, 22-F at the atrial
eptum, and is delivered with a
apered dilator. A dial on the
roximal end of the guide cath-
ter allows deflection of the distal
ip. The Clip Delivery System
CDS) has the MitraClip at-
ached to its distal end. This
ystem uses 2 dials that permit
edial-lateral and anteroposte-
ior steering. The MitraClip device (Fig. 2) is a 4-mm wide
obalt/chromium implant with 2 arms, which are opened
nd closed by a mechanism on the CDS handle. On the
nner portion of the clip are 2 “grippers” adjacent to each
rm to secure the leaflets as they are “captured” during
losure of the arms. Each leaflet is independently secured
etween an arm and a gripper. The clip has a locking
echanism to maintain closure. The clip arms and grippers
re covered with polyester fabric to promote tissue in-
rowth.
rocedural technique. The procedure is performed, with
he patient under general anesthesia, with the use of
uoroscopy and transesophageal and, on occasion, transtho-
acic, echocardiographic guidance. After transseptal punc-
ure, heparin is administered. The transseptal sheath is
xchanged for the steerable guide catheter and dilator. The
DS is introduced into the guide catheter, and the Mitra-
lip device is advanced into the left atrium. By the use of
chocardiographic and fluoroscopic guidance, the clip is
teered until axially aligned and centered over the origin of
he regurgitant jet. The clip is opened to extend the 2 arms
nd advanced into the left ventricle (LV) below the mitral
eaflets. The clip is retracted until both leaflets are grasped
nd then closed to coapt the mitral leaflets. Leaflet insertion
nto the clip and MR reduction are assessed by the use of
-dimensional and Doppler echocardiography. If necessary,
he clip can be reopened and the leaflets released and then
epositioned. If the clip must be withdrawn into the left
trium, the arms may be inverted in the ventricle, providing
smooth profile for retraction to prevent entangling the
hordae tendinea. After adequate reduction of MR has been
chieved under hemodynamic challenge, the clip is de-
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
APS  acute procedural
success
ASE  American Society of
Echocardiography
CDS  Clip Delivery
System
LV  left ventricle
MAE  major adverse
event
MR  mitral regurgitation
MV  mitral valve
NYHA  New York Heart
Association
STS  Society of Thoracic
Surgeonsloyed, and the CDS and guide catheter are withdrawn.
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Percutaneous Mitral Repair With the MitraClip System August 18, 2009:686–94fter the first 10 patients were enrolled, the protocol was
evised to allow a second clip placement if needed. Repeat
emodynamic and echocardiographic assessments were per-
ormed after clip placement. Patients were treated with
spirin 325 mg daily for 6 months and clopidogrel 75 mg
aily for 30 days.
atient selection. Patients were selected if they met class I
ndications for intervention from the 1998/2006 American
ollege of Cardiology (ACC)/American Heart Association
AHA) Joint Task Force recommendations regarding ther-
py for valvular heart disease (9,10). Patients with
oderate-to-severe (3) or severe (4) functional or degen-
rative MR with symptoms, or if asymptomatic, with compro-
ised LV function (ejection fraction 60% or end-systolic
imension 45 mm) were candidates (Table 1). All echocar-
iograms were assessed by an independent core echocardio-
raphic laboratory (University of California at San Francisco,
an Francisco, California). Mitral regurgitation was graded
ccording to the criteria of the American Society of
chocardiography (ASE) guidelines by the use of quanti-
ative (regurgitant volume, regurgitant fraction) and quali-
ative (color Doppler and pulmonary venous flow) criteria
11,12). To be included, moderate-to-severe (3) or severe
4) MR by use of the integrative approach per the ASE
uidelines (Table 2) was required. Key anatomic inclusion
riteria included a regurgitant jet origin associated with the
2 to P2 segments of the mitral valve and, for patients with
unctional MR, a coaptation length of at least 2 mm, a
oaptation depth of no more than 11 mm, and for patients
ith leaflet flail, a flail gap 10 mm and a flail width 15
m (Fig. 3). All patients were candidates for MV surgery,
n the event surgery was required for potential complica-
Figure 2 The MitraClip Device
The device is covered with polyester fabric to facilitate tissue in-growth. The
distal gripping element helps with leaflet fixation. The clip delivery system exits
through a guide catheter.ions. Major exclusions are shown in Table 1.ata analysis. The data from all 107 patients were ana-
yzed per the EVEREST II protocol definitions and pre-
pecified end points. Patients who did not receive a clip or
nderwent MV surgery after the clip implant did not have
urther follow-up during the first part of the study (8).
rimary end points were analyzed for the per-protocol
opulation, defined as patients receiving a clip implant with
eduction of MR to 2, also referred to as acute proce-
ural success (APS). The composite primary safety end
oint was major adverse events (MAEs) at 30 days, defined
s freedom from death, myocardial infarction, nonelective
ardiac surgery for adverse events, renal failure, transfusion
f 2 U of blood, reoperation for failed surgery, stroke,
astrointestinal complications requiring surgery, ventilation
or48 h, deep wound infection, septicemia, and new onset
f permanent atrial fibrillation (determined at 12 months).
he composite primary efficacy end point was freedom from
R 2, freedom from cardiac surgery for valve dysfunc-
ion, and freedom from death at 12 months.
Echocardiograms were performed by the use of a pre-
pecified protocol at baseline; pre-discharge; at 1, 6, 12, 18,
nd 24 months; and yearly up to 5 years. The 12-month
ollow-up MR reduction goal was defined as MR severity of
2, based on the ACC/AHA guidelines (9,10). The goal
n the cardiac catheterization laboratory was to reduce MR
o mild (1) or less with optimal placement of the Mitra-
lip device. An overall MR grade was assigned by use of the
ntegrative method defined by the ASE guidelines (11,12).
ena contracta width and regurgitant orifice area were
ecorded but not included as parameters for MR assessment
ecause they have not been validated for a double orifice
alve. To evaluate for the potential development of MV
tenosis, MV area measured by planimetry, pressure half-
ime, and peak and mean gradients were assessed. After
ercutaneous mitral repair, each of the 2 orifices was
lanimetered at the level of the clip and summed to
etermine valve area.
ey Eligibility Criteria and Key Exclusion CriteriaTable 1 Key Eligibility Criteria and Key Exclusion Criteria
Key inclusion criteria
Candidate for mitral valve repair or replacement surgery
Moderate to severe (3) or severe (4) chronic mitral valve regurgitation and
symptomatic with LVEF 25% and LVID-s 55 mm or asymptomatic
with 1 or more of the following:
LVEF 25% to 60%
LVID-s 40 to 55 mm
New onset of atrial fibrillation
Pulmonary hypertension defined as pulmonary artery systolic pressure
50 mm Hg at rest or 60 mm Hg with exercise.
Key exclusion criteria
Recent myocardial infarction
Any interventional or surgical procedure within 30 days of the index procedure
Mitral valve orifice area 4 cm2
Renal insufficiency, endocarditis, rheumatic heart disease
Previous mediastinal surgery in the first 27 patientsLVEF  left ventricular ejection fraction; LVID-s  left ventricular internal diameter-systole.
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August 18, 2009:686–94 Percutaneous Mitral Repair With the MitraClip Systemesults
ne hundred seven patients were treated, including patients
79%) with degenerative or combined degenerative and
unctional disease and 23 patients (21%) with pure func-
ional MR. Clinical features are shown in Table 3. The
edian age was 71 years (range 26 to 88 years), and 62% of
atients were older than 65 years of age. Among patients
ith functional MR, there was a history of coronary artery
isease in 74% and previous bypass surgery in 43%.
Figure 3 Key Anatomic Eligibility Criteria
The coaptation length must be at least 2 mm. Coaptation depth must be 11 mm
width must be 15 mm. These anatomic characteristics are necessary for sufficie
itral Regurgitation Grade Criteria*Table 2 Mitral Regurgitation Grade Criteria*
Variable Mild 1 Moderate 2
Color flow Doppler Small Moderate
Central Central
4 cm2 or10%
of LA area
46 cm2 or 10% to 3
of LA area
Pulmonary vein flow Systolic dominant Diastolic dominant
Regurgitant volume
(ml/beat)
30 3044
Regurgitant fraction (%) 30 3039
Based on the American Society of Echocardiography published guidelines for the quantitation of
LA  left atrium; PV  pulmonary vein.One clip was placed in 65 patients (61%), 2 clips in 31
atients (29%), and no clips in 11 patients (10%; inability to
educe MR in 8 patients [7%] and transseptal complications
n 3 patients [3%]). Two patients underwent reintervention
o have a second clip placed. There was a steep procedural
earning curve, with rapid reduction in the procedure and
evice times throughout the study. For all patients, includ-
ng those who did not receive a clip, overall procedure time,
efined as the time from transseptal access with the guide
flail leaflet exists, the flail gap must be 10 mm, and the flail
flet tissue for mechanical coaptation when the MitraClip device is used.
Moderate to Severe 3 Severe 4
Large Large
Central Central
6 to 8 cm2 or 30% to 40%
of LA area or eccentric to
first PV
8 cm2 or 40% of LA area or
eccentric to second PV
All diastolic Systolic reversal
4559 60
4049 50
valvular regurgitation, which have not previously been applied in a therapeutic trial (11,12).. If a
nt lea0%
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Percutaneous Mitral Repair With the MitraClip System August 18, 2009:686–94atheter to guide removal from the vein, was 231 min.
evice time, defined as time from guide catheter insertion
o CDS retraction into the guide catheter, was 175 min.
lthough 93% of patients were among the first 3 procedures
t a given site, the overall procedure time decreased to 181
in, with 146 min of device time in the last 30 patients of
his cohort. Currently procedures are frequently completed
ith a device time of approximately 90 min.
In-hospital outcomes are shown in Table 4. There was no
rocedural mortality. Ten patients experienced an MAE at
0 days, resulting in a composite primary safety end point of
.1% (95% confidence interval: 5.1% to 16.3%) by intention
o treat, including a single death in an 81-year-old patient
ith a Society of Thoracic Surgeons (STS) operative mor-
ality risk score of 18.3% in whom no clip was placed and
R was not reduced. One patient with a history of transient
schemic attack had a nonembolic stroke with a neurological
eficit lasting 72 h, which resolved within 30 days.
onelective cardiac surgery was performed in 2 patients for
ransseptal complications. Bleeding requiring transfusion
2 U occurred in 4 patients. One patient underwent
eoperation for failed surgical mitral valve repair 19 days
fter valve repair after an unsuccessful MitraClip procedure,
nd 1 patient required ventilation for 498 h.
Of the 10 patients meeting the MAE safety end point,
lose to one-half received transfusions of 2 U of blood.
aseline Demographics and Clinical FeaturesTable 3 Baseline Demographics and Clinical Features
Baseline (n  107)
Median age (yrs), median (range) 71 (2688)
Age 65 yrs, % 62
Male sex, % 62
Diabetes mellitus, % 21
Hypertension, % 69
Chronic obstructive pulmonary disease, % 12
History of congestive heart failure, % 53
History of coronary artery disease, % 36
Previous coronary artery bypass graft, % 20
Atrial fibrillation, % 29
Ejection fraction, % (median) 62
New York Heart Association functional class III or IV, % 46
n-Hospital OutcomesTable 4 In-Hospital Outcomes
In-Hospital Outcomes* Incidence (n  107)
Death unrelated to MitraClip device 1 (0.9)†
Mechanical ventilation 48 h 2 (1.8)†‡
Bleeding requiring transfusion 2 U (procedural) 4 (3.7)‡
Bleeding requiring transfusion 2 U (post-MV surgery) 1 (0.9)
Transseptal complications 3 (2.8)‡
Renal failure or dialysis 0 (0)
Length of hospital stay, days 3.2 3.9
Discharge home (without home health care) 104 (98)
alues are n (%) or mean  SD. *Includes patients that went to surgery after clip procedure (n 
0). †One patient on ventilation subsequently died. ‡One patient experienced a transseptal
omplication leading to mechanical ventilation 48 h and bleeding requiring transfusion 2 U.
MV  mitral valve.n-hospital mortality was 1%. Mitral valve area (planim-
try) was 5.7  1.5 cm2 (n  94) at baseline, 3.2  1.2 cm2
n  73) at discharge, and 3.5  1.1 cm2 (n  62) at 12
onths. The sample size decreased as the result of some
rossover to surgery and patients with incomplete measure-
ents of the dual orifices after clip placement. The smallest
itral valve area by planimetry was 1.9 cm2, and clinically
ignificant stenosis was defined as 1.5 cm2 per the protocol.
No clip embolization has occurred at any time point.
artial clip detachment, defined as detachment of a single
eaflet from the clip, occurred in 10 patients (9%). Partial
lip detachment occurred in 3 patients during the proce-
ure, in 1 before hospital discharge, and in 5 patients
etween discharge and 30 days. Only 1 partial clip detach-
ent occurred after 30 days; MR recurrence without de-
achment was noted on the 6-month echocardiogram and
orsening of MR, and partial clip detachments were de-
ected on the 12-month echocardiogram. None of the
artial clip detachments were associated with urgent inter-
ention and, in all but 1 patient who had recurrent symp-
oms, these events were detected on protocol-driven echo-
ardiography.
Overall APS was achieved in 79 of 107, or 74% of
atients. The flow chart (Fig. 4) shows the outcomes among
atients both with and without clip implantation and with
nd without APS. Of the 79 patients with APS, 64% were
ischarged with mild MR (1) and 13% had MR graded as
ild to moderate (1 to 2). Thus, 77% had 2 MR. At
2 months, not including crossover to surgery, 50 of 76
atients (66%) had echocardiographic follow-up and con-
inued with MR 2. Three patients did not have an
chocardiogram performed at 12 months. Fifteen patients
xperienced recurrent MR 2 and have not undergone
V surgery. Of these 15 patients, 3 patients experienced a
-grade MR reduction with improved symptoms, and 12
atients continued with no MR reduction from baseline. Of
Figure 4 Efficacy Results Through Discharge
This chart shows the flow of patients from the point of clip procedure attempt
through hospital discharge. *Acute procedural success (APS) is defined as
placement of 1 or more clips resulting in a discharge mitral regurgitation (MR)
severity of 2, as determined by the Core Laboratory.
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August 18, 2009:686–94 Percutaneous Mitral Repair With the MitraClip Systemhe remaining 11 APS patients, 9 experienced recurrent MR
nd underwent MV surgery during the first year of follow-
p, 1 of whom died after surgery, 1 with ongoing MR2
ied in the first year, unrelated to the clip, and 1 patient
ith 3 MR at 6 months died of cardiac arrest before 12
onth follow-up. As previously reported, no mitral stenosis
ccurred (13).
Of the 106 patients who were discharged from the
ospital, 104 (98%) were discharged to home with self care,
hereas the remaining 2 patients in whom MR was not
educed sufficiently with the clip underwent MV surgery
uring the index hospitalization and were discharged to a
ardiac rehabilitation facility.
On an intent-to-treat basis, 96 (90%) of 107 patients
uccessfully achieved a reduction in MR from either the clip
r subsequent MV surgery after attempted clip. Of the
emaining 11 patients who did not achieve MR reduction to
2 after the clip, 10 patients did not undergo MV surgery
fter unsuccessful clip attempt, and 1 patient underwent
V replacement surgery 19 days after failed MV repair
urgery. Seventy percent (75 of 107) of patients remained
urgery free after a median follow-up of 680 days. The
emaining 32 patients underwent MV surgery after a clip
rocedure. Twenty-three patients had MV surgery after clip
mplantation, and 9 patients had surgery after no clip was
mplanted. Surgery was performed 14  21 days after the
rocedure in cases where no clip was implanted and 234 
19 days after surgery in cases in which a clip had been
laced (p  0.003).
The pre-operative strategy was known for 31 of 32
atients who underwent surgery after a clip procedure. In
hese 31 patients, 87% of surgeries (27 of 31) were per-
ormed as planned pre-operatively, whereas 13% (4 of 31) of
atients had replacement after attempted repair (3 repairs
onverted to replacement intraoperatively, 1 patient under-
ent MV replacement 19 days after failed MV repair) (Fig. 5)
14). When repair was planned after a clip procedure, 84%
21 of 25) were successfully repaired. When MV replace-
ent was performed, the majority (60%, 6 of 10) of
eplacements were planned because of complex disease,
dvanced age, and/or comorbidities. One additional re-
lacement occurred without a known pre-operative strategy.
uccessful surgical repair with clip removal was performed
p to 18 months after percutaneous mitral repair. In
ummary, surgical options were preserved.
The composite primary efficacy end point (freedom from
R 2, freedom from cardiac surgery for valve dysfunc-
ion, and freedom from death for the per-protocol popula-
ion at 12 months) was 66% (95% confidence interval: 55%
o 75%). Of the 65 patients with matched New York Heart
ssociation (NYHA) functional class data at baseline and
2 months, baseline NYHA functional class was I/II in 29
atients (45%) and III/IV in 36 patients (55%). At 12
onths, 60 patients (92%) were NYHA functional class
/II, and 5 patients (8%) were III/IV. Clinical symptoms
ere improved in 74% of patients, 21% had no change in tymptoms, and 6% (3 of 65) had worsened symptoms. The
patients with worsened symptoms each had mild MR
1) at 12-month follow-up. Of these 3 patients, 1 patient
orsened from NYHA functional class II to class IV after
xperiencing chest pain requiring cardiac catheterization
ith angioplasty and stenting at 12 months; 1 patient
ncreased to NYHA functional class II after a complaint of
typical chest pain, which resolved without treatment at 12
onths; and the remaining patient experienced an increase
o NYHA functional class II at 6 months without any
eported adverse events. This patient remained at NYHA
unctional class II at 12 months. In patients continuing with
clip implant at 12 months with matched data, the
eptal-lateral annular diameter was stable. The mean annu-
ar septal-lateral dimension in systole and diastole was 3.3
.4 cm and 3.8  0.4 cm at baseline and 3.4  0.4 cm and
.9  0.4 cm at 12 months (p  0.76 and p  0.21, n 
5), respectively.
In the APS cohort, Kaplan-Meier freedom from death
as 95.9%, 94.0%, and 90.1% at 1, 2, and 3 years, and
aplan-Meier freedom from surgery was 88.5%, 83.2%,
nd 76.3% at 1, 2, and 3 years, respectively (Fig. 6). The
3 patients with functional MR had similar acute results
nd durability compared with the overall population.
atients with functional MR achieved 83% APS and
xhibited an 80% improvement in symptoms from base-
ine to 12 months, with freedom from surgery of 94.1% at
years.
iscussion
e report the initial experience with the MitraClip system
n North America. Seventy percent of this experience
onsists of the participating centers’ first 3 procedures. The
esults from the initial experience in this prospective, mul-
icenter trial indicate that percutaneous mitral repair with
Figure 5 Surgical Patient Flow Chart
Flow chart depicting the outcomes of
patients who had surgery after a clip attempt. MV  mitral valve.he use of the MitraClip device can be successfully accom-
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Percutaneous Mitral Repair With the MitraClip System August 18, 2009:686–94lished with MR reduction to less than moderate (2) in
he majority of patients and with low mortality and mor-
idity. Freedom from death, need for surgery, or recurrent
R 2 was sustained in a substantial proportion of the
nitial patient cohort. Furthermore, among those patients
equiring MV surgery for residual or recurrent MR, surgical
ptions were preserved, with standard repair techniques
afely performed in the large majority of patients consistent
ith contemporaneous surgical repair rates.
The open heart surgical technique creates a double orifice
y permanently coapting the MV scallops with a suture at
he origin of MR. Excellent results when using this ap-
roach (without annuloplasty or leaflet resection) in selected
atients with degenerative or functional MR have been
eported with up to a 12-year follow-up (4). The MitraClip
evice is based on the surgical double orifice approach that
ses a clip rather than suture to secure the mitral leaflets and
s performed on the beating heart.
To ensure that a patient population in need of therapy
nd well suited for mitral repair with the MitraClip device
as selected, the prospective use of echocardiograms was
trictly used. The severity of MR and LV function require-
ents were used to ensure that patients had to have
oderate-to-severe (3) or severe (4) MR. The protocol
xcluded patients with dilated LV (ejection fraction 25%
r an LV dimension 55), coaptation length of 2 mm,
nd coaptation depth 11 mm in whom annuloplasty
requently has poor results.
All patients enrolled had a guideline-supported indi-
ation for mitral valve surgery. The mean MR grade at
Figure 6 Kaplan-Meier Curves for Patients With Acute Procedu
Freedom from death and freedom from surgery are depicted.aseline was 3.3  0.7. Patients in the EVEREST trial tave a more severe degree of MR than patients reported
n many surgical repair series, which infrequently report
re-operative MR (15–17). The median age of 71 years is
2 years older than the typical first-time isolated surgical
epair patient reported in the 2007 STS database (median
ge of 59 years for repair and 61 years for replacement,
espectively) (18).
There has been substantial learning along a steep curve.
rocedure time for the first 30 procedures was a median of
41 min, whereas the final 30 procedures of this cohort were
full 1 h shorter (median time 181 min), despite almost all
f the procedures representing early learning experience for
ndividual centers. For reference, the 2007 STS database
ists a median cross clamp time of 79 min, a median
ardiopulmonary bypass time of 110 min, and approxi-
ately 230 min for the entire procedure (“skin to skin”) for
solated MV repair in the hands of experienced cardiac
urgeons (16). Efficient echocardiographic guidance is es-
ential for this procedure, and a substantial amount of the
earning can be attributed to optimizing the use of this
odality (19).
One remarkable feature of the MitraClip procedure is the
emodynamic stability of patients during the procedure.
espite the fact that a device is being manipulated within
he mitral orifice in a beating heart, hypotension or signif-
cant ventricular arrhythmias are rarely observed. Percuta-
eous mitral repair procedures have been uniformly well
olerated.
Procedural safety has been demonstrated. The complica-
ions to date are primarily related to either cardiac cathe-
ccessre Suerization in general, the transseptal procedure, or to surgery
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August 18, 2009:686–94 Percutaneous Mitral Repair With the MitraClip Systemfter clip treatment. The most important complication
pecifically related to the clip has been partial clip detach-
ent, not clip embolization. All but 1 partial clip detach-
ent was detected on protocol-driven echocardiograms,
nd none were associated with emergent or urgent surgery
r precipitous clinical deterioration.
The rates of discharge from the hospital directly home are
reater and hospital stay shorter than for MV surgery.
mportantly, 106 (99.1%) of the 107 patients were dis-
harged, and 104 (98%) of the 106 patients were discharged
ome with self-care. The 2 remaining patients (2%) who
eeded nursing care had surgery while hospitalized for the
itraClip procedure. This finding is in contrast to surgery,
ven with less-invasive surgical approaches. According to
he Diagnosis Related Group handbook (20) diagnosis-
elated group 104 (cardiac valve and other major procedure
ith cardiac catheterization), 92.5% of patients are dis-
harged, and only 40% are discharged home with self-care.
or diagnosis-related group 105 (cardiac valve and other
ajor procedure without cardiac catheterization), 95.5% of
atients are discharged, and only 53.9% are discharged
ome with self-care.
Surgical repair was performed after procedures in which
o clip was placed or when a clip was removed during
urgery in the majority of patients, which is relevant because
atients selected for inclusion in the EVEREST trial were
ot required to be repairable surgically. To 12 months, 94
88%) of the 107 patients had a successful repair procedure
either percutaneous or surgical repair). Options for surgery
ere not diminished by a clip procedure because all patients
equiring surgery after a clip procedure, whether they were
mplanted with the clip or not, were able to have mitral
epair or replacement surgery (14). A large proportion
87%) of surgical procedures was performed as planned
re-operatively, and 84% of attempted surgical repairs after
lip procedures were successful. This finding is comparable
ith the predicted repair rate reported for surgery based on
re-operative TEE (21,22). Successful surgical repair was
erformed as late as 18 months after a MitraClip procedure.
ost surgical replacements were planned pre-operatively as
he result of complex disease, advanced age, or comorbidities.
Neither the 1998 nor the 2006 ACC/AHA guidelines
ecommend surgery for MR severity of less than severe
graded at least 3 or 4 in this study). The protocol MR
fficacy goal was defined as MR severity of less than or equal
o moderate (2) after clip placement. The obvious proce-
ural goal of percutaneous mitral repair is to reduce MR as
uch as possible, and in this study the procedural goal was
o reduce MR to mild (1) or less with optimal placement
f the MitraClip device.
Although the experience with pure functional MR is
maller, 23 patients had similar 12-month durability com-
ared with the overall population, supporting its use regard-
ess of whether the etiology is functional MR or degenera-
ive MR, provided sufficient tissue is available for coaptation
ith the clip. It has been demonstrated in both animal and fuman explants that a tissue bridge forms across the clip
etween the leaflets (7,23,24). This healing response may
elp prevent future annular dilation (25). It has been
ypothesized that the clip-initiated tissue bridge provides
upport for the clip repair (in a way partially similar to
nnuloplasty) and helps prevent septal-lateral dilation, as
hown by the stable septal-lateral dimensions through the
2 months reported for this cohort. Preserving annular
ontractile function by avoiding annuloplasty may be an
dvantage, especially in patients with decreased LV and
nnular function.
The clinical application of this therapy will depend on
nitial MR reduction and the duration of sustained MR
eduction. The recurrence of MR also has been described
fter successful surgical repair with linearized recurrence
ates of 1 MR of 8.3% per year and of 2 MR of
.7% per year (26,27). Whether the MR reduction achieved
ith percutaneous repair is adequate also depends on the
oals of therapy. For example, an octogenarian with multi-
le comorbid conditions may derive clinical benefit despite
uboptimal MR reduction compared with a young patient
ith no problem other than severe MR.
Several theoretical concepts support the potential value
f this percutaneous approach for the treatment of MR.
irst, when MR from degenerative or functional disease
esults in mechanical leaflet malcoaptation, it may be
menable to the mechanical solution provided by the
itraClip device. Second, healing associated with clip
esults in a tissue bridge, which supports the clip repair.
his tissue bridge may help support the mitral annulus, thus
voiding septal-lateral annular dilation without impairing
nnular contractile function. Additionally, continuity cre-
ted through the tissue bridge between the annulus, the
eaflets, the chordate, and the papillary muscles also may
elp prevent dilation of the LV. Finally, providing a method
or reducing MR that avoids concomitant injury to the heart
ay provide an improved treatment outcome. Specifically,
fter open arrested heart surgery, there is abnormal LV
eptal motion that may affect overall LV function (28). This
henomenon has not been observed following percutaneous
itral valve repair.
This prospective, multicenter, core laboratory moni-
ored experience with a novel first-in-class device for
ercutaneous MR therapy demonstrated acute reduction
f MR in the majority of patients, with sustained
reedom from death, need for surgery, or recurrent MR
2 in a substantial proportion of patients after 1 year in
he initial patient cohort. Annular diameter was stable
hrough 12 months, indicating absence of further annular
ilation. This cohort also experienced improved symp-
oms, indicating that clinical benefit was associated with
he achieved MR reduction. A randomized comparison of
ercutaneous repair with the MitraClip device to surgical
alve repair or replacement is underway, and 12-month
ollow-up in a 78-patient high-risk registry of patients
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ecently been completed.
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APPENDIX
or a complete list of the Evalve Investigators, please see the online version
f this article.
